EE03951B1 - Inhaleeritav ravimvorm puistetihedusega 0,28 kuni0,38 g/ml, selle valmistamise protsess ja kasutamine - Google Patents

Inhaleeritav ravimvorm puistetihedusega 0,28 kuni0,38 g/ml, selle valmistamise protsess ja kasutamine

Info

Publication number
EE03951B1
EE03951B1 EEP199900295A EEP9900295A EE03951B1 EE 03951 B1 EE03951 B1 EE 03951B1 EE P199900295 A EEP199900295 A EE P199900295A EE P9900295 A EEP9900295 A EE P9900295A EE 03951 B1 EE03951 B1 EE 03951B1
Authority
EE
Estonia
Prior art keywords
preparation
dosage form
bulk density
inhalation dosage
inhalation
Prior art date
Application number
EEP199900295A
Other languages
English (en)
Estonian (et)
Inventor
Trofast Jan
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03951(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9900295A publication Critical patent/EE9900295A/xx
Publication of EE03951B1 publication Critical patent/EE03951B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP199900295A 1997-01-20 1998-01-13 Inhaleeritav ravimvorm puistetihedusega 0,28 kuni0,38 g/ml, selle valmistamise protsess ja kasutamine EE03951B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700135A SE9700135D0 (sv) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000040 WO1998031352A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof

Publications (2)

Publication Number Publication Date
EE9900295A EE9900295A (et) 2000-02-15
EE03951B1 true EE03951B1 (et) 2003-02-17

Family

ID=20405455

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900295A EE03951B1 (et) 1997-01-20 1998-01-13 Inhaleeritav ravimvorm puistetihedusega 0,28 kuni0,38 g/ml, selle valmistamise protsess ja kasutamine

Country Status (34)

Country Link
US (2) US6030604A (cs)
EP (1) EP1007017B2 (cs)
JP (1) JP2010059181A (cs)
KR (1) KR100528416B1 (cs)
CN (1) CN1271993C (cs)
AR (1) AR011080A1 (cs)
AT (1) ATE288260T1 (cs)
AU (1) AU731192B2 (cs)
BR (1) BR9811249A (cs)
CA (1) CA2277913C (cs)
CZ (1) CZ296301B6 (cs)
DE (1) DE69828886T3 (cs)
DK (1) DK1007017T4 (cs)
EE (1) EE03951B1 (cs)
ES (1) ES2235311T5 (cs)
HU (1) HU228622B1 (cs)
ID (1) ID21865A (cs)
IL (1) IL130838A (cs)
IS (1) IS2788B (cs)
MY (1) MY132999A (cs)
NO (1) NO327426B1 (cs)
NZ (1) NZ336594A (cs)
PL (1) PL192115B1 (cs)
PT (1) PT1007017E (cs)
RU (1) RU2194497C2 (cs)
SA (1) SA98180818B1 (cs)
SE (1) SE9700135D0 (cs)
SI (1) SI1007017T2 (cs)
SK (1) SK283950B6 (cs)
TR (1) TR199901690T2 (cs)
TW (1) TW557217B (cs)
UA (1) UA57764C2 (cs)
WO (1) WO1998031352A1 (cs)
ZA (1) ZA9878B (cs)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
DE69818872T2 (de) * 1998-12-11 2004-05-19 Pharmachemie B.V. Pharmazeutische zubereitungen zur inhalation eines opioids
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6623760B1 (en) * 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
CA2369262A1 (en) * 1999-04-13 2000-10-19 Sudha Nagarajan Pulmonary administration of dry powder formulations for treating infertility
CA2273585A1 (en) 1999-05-28 2000-11-28 Canpolar East Inc. Sensors for detecting changes in temperature, ph, chemical conditions, biological conditions, radiation, electrical field and pressure
EP1183061B2 (en) 1999-06-05 2012-10-17 Innovata Biomed Limited Medicament delivery system
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
DE19962926A1 (de) * 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
US20030026766A1 (en) * 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
WO2002062317A2 (en) * 2001-02-06 2002-08-15 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
CA2484272A1 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
PL375819A1 (en) * 2002-12-12 2005-12-12 Altana Pharma Ag Combination medicament
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
US20060293293A1 (en) * 2003-05-22 2006-12-28 Altana Pharma Ag Salmeterol and ciclesonide combination
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005020963A1 (en) 2003-09-02 2005-03-10 Ivax Corporation Process for preparing a medicament
ES2452691T5 (es) * 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
AU2005214153B2 (en) * 2004-01-22 2008-09-18 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
AR048339A1 (es) * 2004-03-24 2006-04-19 Chiesi Farma Spa Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
BRPI0509348A (pt) 2004-04-21 2007-09-11 Innovata Biomed Ltd inalador
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
CA2591406A1 (en) * 2004-12-17 2006-06-22 Cipla Limited Pharmaceutical compounds and compositions
JP5156397B2 (ja) * 2005-02-10 2013-03-06 グラクソ グループ リミテッド 予備分級技術を用いて乳糖を製造する方法及びその乳糖から形成させた医薬製剤
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
EP1906919A4 (en) * 2005-07-15 2012-12-26 Map Pharmaceuticals Inc MULTIPLE ACTIVE PHARMACEUTICAL PRINCIPLES COMBINED IN DISCRETE INHALATION PARTICLES AND THEIR FORMULATIONS
AU2006272438B2 (en) * 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
WO2008100727A2 (en) 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110135737A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
KR101638301B1 (ko) * 2010-01-15 2016-07-08 네오쎄틱스 인코포레이티드 동결건조 케이크 제제
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
BR112013008974A2 (pt) 2010-10-12 2023-12-19 Cipla Ltd Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica
BR112013012994A2 (pt) 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
JP2015512929A (ja) 2012-04-11 2015-04-30 シプラ・リミテッド 医薬組成物
RU2510267C2 (ru) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
AU2014228414B2 (en) 2013-03-15 2018-09-13 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ES2662847T3 (es) 2013-07-01 2018-04-10 Arven Ilac Sanayi Ve Ticaret A.S. Formulaciones novedosas de inhalación
WO2019036483A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation AQUEOUS NEBULIZATION COMPOSITION
MX2021014343A (es) * 2019-05-24 2022-01-06 Glenmark Pharmaceutical Ltd Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) † 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) † 1988-11-01 1988-12-07 Fisons Plc Formulation
CA2058764A1 (en) * 1989-04-28 1990-10-29 Peter D. Hodson Dry powder inhalation device
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DK0441740T3 (da) † 1990-01-29 1993-11-08 Ciba Geigy Ag Fremgangsmåde og apparat til dosering af et firkornet pulver
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
DE69208660T2 (de) * 1991-06-10 1996-07-11 Schering Corp., Kenilworth, N.J. Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
CA2115065C (en) † 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
EP0665010B1 (en) * 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
BR9407287A (pt) * 1993-08-18 1996-10-01 Unilever Nv Composição para barbear
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
SG48049A1 (en) † 1993-10-01 1998-04-17 Astra Ab Process i
GB9404945D0 (en) † 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation

Also Published As

Publication number Publication date
DK1007017T3 (da) 2005-05-02
SE9700135D0 (sv) 1997-01-20
PL334527A1 (en) 2000-02-28
NO993539D0 (no) 1999-07-19
KR100528416B1 (ko) 2005-11-16
DE69828886T3 (de) 2011-06-01
SI1007017T1 (en) 2005-06-30
IL130838A (en) 2005-07-25
SK283950B6 (sk) 2004-05-04
ES2235311T3 (es) 2005-07-01
HK1025515A1 (en) 2000-11-17
PT1007017E (pt) 2005-05-31
RU2194497C2 (ru) 2002-12-20
CN1271993C (zh) 2006-08-30
US6030604A (en) 2000-02-29
PL192115B1 (pl) 2006-08-31
EP1007017B1 (en) 2005-02-02
KR20000070188A (ko) 2000-11-25
UA57764C2 (uk) 2003-07-15
TW557217B (en) 2003-10-11
JP4512204B2 (ja) 2010-07-28
AU5785998A (en) 1998-08-07
SA98180818B1 (ar) 2006-03-25
DE69828886D1 (de) 2005-03-10
IS2788B (is) 2012-06-15
TR199901690T2 (xx) 1999-09-21
NO327426B1 (no) 2009-06-29
CN1243436A (zh) 2000-02-02
SK95999A3 (en) 2000-01-18
US6287540B1 (en) 2001-09-11
CZ255799A3 (cs) 1999-10-13
DK1007017T4 (da) 2011-02-28
CZ296301B6 (cs) 2006-02-15
ZA9878B (en) 1998-07-20
ES2235311T8 (es) 2011-05-13
JP2010059181A (ja) 2010-03-18
EE9900295A (et) 2000-02-15
HU228622B1 (en) 2013-04-29
IS5108A (is) 1999-07-06
ES2235311T5 (es) 2011-03-31
JP2001508793A (ja) 2001-07-03
CA2277913C (en) 2007-03-06
AU731192B2 (en) 2001-03-29
SI1007017T2 (sl) 2011-03-31
BR9811249A (pt) 2000-09-05
EP1007017B2 (en) 2010-12-08
NZ336594A (en) 2001-01-26
DE69828886T2 (de) 2006-04-06
EP1007017A1 (en) 2000-06-14
HUP0000714A3 (en) 2000-10-30
CA2277913A1 (en) 1998-07-23
HUP0000714A2 (hu) 2000-08-28
NO993539L (no) 1999-09-20
IL130838A0 (en) 2001-01-28
WO1998031352A1 (en) 1998-07-23
ID21865A (id) 1999-08-05
AR011080A1 (es) 2000-08-02
MY132999A (en) 2007-10-31
ATE288260T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
EE03951B1 (et) Inhaleeritav ravimvorm puistetihedusega 0,28 kuni0,38 g/ml, selle valmistamise protsess ja kasutamine
EE9700031A (et) Pürido-liitunud tienüül- ja furanüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
EE9700020A (et) Heteroaatomit sisaldavad tsülopentaanpüridüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9700043A (et) Asendatud oksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9700060A (et) 2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
FI962900A7 (fi) Redispergoituvat, piimodifioidut dispersiojauheseokset, menetelmä niid en valmistamiseksi ja niiden käyttö
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
EE9700153A (et) Heterotsükliga kondenseerunud püridiinid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
Petri Diagnosis of antiphospholipid antibodies
EE9700019A (et) 2-okso- ja 2-tio1,2-dihüdrokinolinüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
IS3878A (is) Imidazodiazepines efnasambönd, framleiðsla þeirraog notkun sem lyfja
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
IL148870A0 (en) 2'-substituted 1, 1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
ITRM920412A0 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
IL156262A0 (en) Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
ZA951374B (en) Ranitidine solid dosage form
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
FI970997A7 (fi) Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ITMI912261A0 (it) Composizioni farmaceutiche contenenti clozapina, loro preparazione e loro impiego
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
IT1277835B1 (it) Composti biciclici, loro preparazione ed uso in composizioni farmaceutiche

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231